Amicus Pompe Disease Combo’s Approvability In Question As Key Trial Misses Mark
Company Touts ‘Totality Of Data’ As Supporting Approval
Executive Summary
The company hopes to score a nod from the US FDA based on a secondary endpoint that won approval for Sanofi’s Lumizyme.
You may also be interested in...
Amicus Spins Out Rare Disease Gene Therapy Pipeline, Raises $200m
While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.
Orphan Drugs Dominate EU Fast-Track Request Decisions In July
The European Medicines Agency decided this month whether to grant fast-track review for planned marketing authorization applications for three potential new orphan treatments.
GSK’s Shingrix On Recovery Track In Q3 After Pandemic Slump
The shingles vaccine’s move to health care practices, as well as inventory moves, contributed to its 41% sales growth during the quarter after a difficult year due to COVID-19.